Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its third-quarter 2024 investor ...

Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

The lowered sales forecast, which analysts called a “shocking guidance update,” contributed to a 23% drop in the cancer ...

Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.

Bernstein analyst Eve Burstein raised the firm’s price target on Exact Sciences (EXAS) to $90 from $75 and keeps an Outperform rating on ...

The firm's analyst highlighted the solid momentum of Exact Sciences' Cologuard business, noting a Compound Annual Growth Rate (CAGR) of approximately 31% from 2021 to 2023 for the product.

Exact Sciences, which is behind brands Cologuard and Oncotype DX, said it will combine CancerSEEK with its scientific platform, clinical organization, and commercial infrastructure. The company ...

PHILADELPHIA (WPVI) -- Bill Nye "The Science Guy" encouraged Philadelphia residents to vote in this year's election. He spoke at a "Party to the Polls Purple Tour" on Tuesday morning in ...

While the prevalence of financial precarity varied by scenario, the proportion of beneficiaries who could not pay their hospital bill across ... stool DNA test (Exact Sciences Cologuard) vs.

ACG abstracts are available on the meeting website. “Exact Sciences is pleased to share new modeling data which demonstrates the Cologuard Plus test as an efficient CRC screening strategy across ...

ACG abstracts are available on the meeting website. “Exact Sciences is pleased to share new modeling data which demonstrates the Cologuard Plus test as an efficient CRC screening strategy across ...